4//SEC Filing
ROTHBLATT MARTINE A 4
Accession 0001106578-25-000041
CIK 0001082554other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:08 PM ET
Size
23.9 KB
Accession
0001106578-25-000041
Insider Transaction Report
Form 4
ROTHBLATT MARTINE A
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$120.26/sh+4,000$481,040→ 4,130 total - Sale
Common Stock
2025-12-15$491.77/sh−500$245,885→ 3,630 total - Sale
Common Stock
2025-12-15$495.14/sh−3,500$1,732,984→ 130 total - Exercise/Conversion
Common Stock
2025-12-16$120.26/sh+4,000$481,040→ 4,130 total - Sale
Common Stock
2025-12-16$492.49/sh−2,500$1,231,235→ 1,630 total - Sale
Common Stock
2025-12-16$494.00/sh−1,000$494,000→ 630 total - Sale
Common Stock
2025-12-16$497.17/sh−500$248,585→ 130 total - Exercise/Conversion
Stock Option
2025-12-15−4,000→ 14,000 totalExercise: $120.26From: 2020-03-15Exp: 2026-03-15→ Common Stock (4,000 underlying) - Exercise/Conversion
Stock Option
2025-12-16−4,000→ 10,000 totalExercise: $120.26From: 2020-03-15Exp: 2026-03-15→ Common Stock (4,000 underlying)
Holdings
- 166(indirect: By Spouse)
Common Stock
- 324,518(indirect: By Trust)
Common Stock
- 258,117(indirect: By Trust)
Common Stock
- 45,596(indirect: By Trust)
Common Stock
- 10,962(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $494.94 to $495.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $492.245 to $492.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- [F5]Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- [F6]Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- [F7]Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Documents
Issuer
UNITED THERAPEUTICS Corp
CIK 0001082554
Entity typeother
Related Parties
1- filerCIK 0001106578
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:08 PM ET
- Size
- 23.9 KB